Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: an AURELIA substudy

Abstract

NCT00976911.

Quality of Life of Patients With Ovarian Cancer of the Third Stage Using Differentiated Treatment

“…OC relapse has a negative psychological and physical impact, highlighting the importance of time without recurrence and the need for effective treatment in the long term [14]. Quality of life predicts overall survival in women with platinum-resistant ovarian cancer as it was demonstrated in AURELIA substudy [15].…”

Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG symptom benefit study (SBS)

“…To our knowledge, there have been no analyses published investigating prognostic factors to identify patients with PPSROC!3 who are likely to stop chemotherapy early due to rapid progression. We have addressed this question for women with platinum-resistant ovarian cancer and found that PF and RF remained significant predictors of stopping chemotherapy early; poorer PF, RF, GHS and worse AGIS were independent predictors of shorter OS; PF, RF and GHS were independent predictors of death within 30 days of chemotherapy [5,6]. The importance of this area of research is supported by the recognition that many patients are treated with chemotherapy in their last month or two of life, which is not considered good practice.…”

“…The ultimate goal being to identify the subset of patients with a particularly poor prognosis and a short survival in whom supportive care would be a better option than chemotherapy. We have previously reported that low baseline global health status (GHS), role function (RF), physical function (PF), and high abdominal/gastrointestinal symptom score (AGIS) were associated with worse outcomes in patients with platinum-resistant ovarian cancer [5,6]. We considered a range of clinicopathologic characteristics previously shown to have prognostic significance at baseline in patients with PPSROC!3, including performance status (PS), neutrophil lymphocyte ratio, thrombocytosis [7e10], aspects of HRQL, and symptoms.…”

Flexible model for patient engagement: Achieving quality outcomes and building a research agenda for head and neck cancer

“…In an era when the vast majority of research is still being conducted without input from its intended beneficiaries, the patients, a few salient points have emerged that force us to question this practice. First, a cancer patient's self‐reported quality of life (QOL) can predict their own survival, independent of other factors . This has been demonstrated in several studies evaluating patients with cancer in general and has long been studied specifically in lung cancer .…”

“…First, a cancer patient's self-reported quality of life (QOL) can predict their own survival, independent of other factors. [1][2][3][4][5][6][7][8][9][10][11][12][13] This has been demonstrated in several studies evaluating patients with cancer in general 4,10-13 and has long been studied specifically in lung cancer. [1][2][3][5][6][7][8][9] In one study, QOL was identified as a more powerful predictor of outcome compared to standard measures such as Karnofsky performance score or staging.…”